1
|
Afari H, Sheehan M, Reza N. Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy. Cardiol Ther 2024; 13:17-37. [PMID: 38340291 PMCID: PMC10899150 DOI: 10.1007/s40119-024-00351-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 01/11/2024] [Indexed: 02/12/2024] Open
Abstract
Cardiovascular disease is the primary cause of pregnancy-related mortality and morbidity in the United States, and maternal mortality has increased over the last decade. Pregnancy and the postpartum period are associated with significant vascular, metabolic, and physiologic adaptations that can unmask new heart failure or exacerbate heart failure symptoms in women with known underlying cardiomyopathy. There are unique management considerations for heart failure in women throughout pregnancy, and it is imperative that clinicians caring for pregnant women understand these important principles. Early involvement of multidisciplinary cardio-obstetrics teams is key to optimizing maternal and fetal outcomes. In this review, we discuss the unique challenges and opportunities in the diagnosis of heart failure in pregnancy, management principles along the continuum of pregnancy, and the safety of heart failure therapies during and after pregnancy.
Collapse
Affiliation(s)
- Henrietta Afari
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 11Th Floor South Pavilion, Philadelphia, PA, 19104, USA
| | - Megan Sheehan
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Nosheen Reza
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 11Th Floor South Pavilion, Philadelphia, PA, 19104, USA.
| |
Collapse
|
2
|
O'Kelly AC, Sarma A, Naoum E, Easter SR, Economy K, Ludmir J. Cardiogenic Shock and Utilization of Mechanical Circulatory Support in Pregnancy. J Intensive Care Med 2024:8850666231225606. [PMID: 38204193 DOI: 10.1177/08850666231225606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2024]
Abstract
Maternal mortality rates are rising in the United States, a trend which is in contrast to that seen in other high-income nations. Cardiovascular disease and hypertensive disorders of pregnancy are consistently the leading causes of maternal mortality both in the United States and globally, accounting for about one-quarter to one-third of maternal and peripartum deaths. A large proportion of cardiovascular morbidity and mortality stems from acquired disease in the context of cardiovascular risk factors, which include obesity, pre-existing diabetes and hypertension, and inequities in care from maternal care deserts and structural racism. Patients may also become pregnant with preexisting structural heart disease, or acquire disease throughout pregnancy (ex: spontaneous coronary artery dissection, peripartum cardiomyopathy), and be at higher risk of pregnancy-related cardiovascular complications. While risk-stratification tools including the modified World Health Organization (mWHO) classification, Cardiac Disease in Pregnancy (CARPREG II) and Zwangerschap bij Aangeboren HARtAfwijking/Pregnancy in Women with Congenital Heart Disease (ZAHARA) have been designed to help physicians identify patients at increased risk for adverse pregnancy outcomes and who may therefore benefit from referral to a tertiary care center, the limitation of these scores is their predominant focus on patients with known preexisting heart disease. As such, identifying patients at risk for pregnancy complications presents a significant challenge, and it is often patients with high-risk cardiovascular substrates prior to or during pregnancy who are at a highest risk for adverse pregnancy outcomes including cardiogenic shock.
Collapse
Affiliation(s)
- Anna C O'Kelly
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Amy Sarma
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Emily Naoum
- Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Sarah Rae Easter
- Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Division of Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Katherine Economy
- Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Jonathan Ludmir
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
3
|
Botti G, Thirunavukarasu S, Ziviello F, Chieffo A. Peripartum Cardiogenic Shock and Mechanical Circulatory Support. Interv Cardiol 2023; 18:e28. [PMID: 38213746 PMCID: PMC10782424 DOI: 10.15420/icr.2020.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2020] [Accepted: 10/08/2023] [Indexed: 01/13/2024] Open
Abstract
Despite remarkable improvements in the past two decades, the annual cardiovascular mortality rate has remained higher for women than for men. Pregnant women represent an underinvestigated population in clinical research, and the mechanisms of long-term cardiovascular complications in women with obstetric complications remain to be elucidated. Regarding advanced heart failure during pregnancy, interventional approaches are effective but still underutilised. Percutaneous mechanical circulatory support is a valuable option for peripartum cardiogenic shock, although its use during pregnancy is still limited. Survival rates have improved in recent years, but further emphasis on the importance of early recognition and initiation of heart failure treatment in this patient group is warranted. The aims of this review are to summarise the current literature on the implementation of mechanical circulatory support in cardiogenic shock during pregnancy and delivery and to understand the role of percutaneous ventricular assist devices in the management of such conditions.
Collapse
Affiliation(s)
- Giulia Botti
- Interventional Cardiology Unit, IRCCS San Raffaele Scientific InstituteMilan, Italy
- Vita Salute San Raffaele UniversityMilan, Italy
| | | | - Francesca Ziviello
- Interventional Cardiology Unit, IRCCS San Raffaele Scientific InstituteMilan, Italy
| | - Alaide Chieffo
- Interventional Cardiology Unit, IRCCS San Raffaele Scientific InstituteMilan, Italy
- Vita Salute San Raffaele UniversityMilan, Italy
| |
Collapse
|
4
|
Perioperative Management of Patients Receiving Short-term Mechanical Circulatory Support with the Transvalvular Heart Pump. Anesthesiology 2022; 136:829-842. [PMID: 35120198 DOI: 10.1097/aln.0000000000004124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
Use of the transvalvular heart pump to provide short-term circulatory support in the perioperative setting is growing. The considerations for the perioperative management of patients receiving transvalvular heart pump support are reviewed for the anesthesiologist.
Collapse
|
5
|
Beavers CJ, DiDomenico RJ, Dunn SP, Cox J, To L, Weeks P, Trujillo TC, Jennings DL. Optimizing anticoagulation for patients receiving Impella support. Pharmacotherapy 2021; 41:932-942. [PMID: 34597429 DOI: 10.1002/phar.2629] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Revised: 09/13/2021] [Accepted: 09/14/2021] [Indexed: 01/12/2023]
Abstract
Anticoagulation of patients treated with the Impella percutaneous mechanical circulatory support (MCS) devices is complex and lacks consistency across centers, potentially increasing the risk of complications. In order to optimize safety and efficacy, an expert committee synthesized all available evidence evaluating anticoagulation for patients receiving Impella support in order to provide consensus recommendations for the management of anticoagulation with these devices. The evidence synthesis led to the creation of 42 recommendations to improve anticoagulation management related to the use of the Impella devices. Recommendations address purge solution management, intravenous anticoagulation, monitoring, evaluation and management of heparin-induced thrombocytopenia (HIT), and management during combination MCS support. The use of a heparinized, dextrose-containing purge solution is critical for optimal device function, and a bicarbonate-based purge solution may be an alternative in certain situations. Likewise, intravenous (ie, systemic) anticoagulation with heparin is often necessary, although evidence supporting the optimal assay and target range for monitoring the level of anticoagulation is generally lacking. Patients treated with an Impella MCS device may develop HIT, which is more difficult to evaluate and treat in this setting. Lastly, the use of Impella with extracorporeal membrane oxygenation or for biventricular support creates additional anticoagulation challenges.
Collapse
Affiliation(s)
- Craig J Beavers
- University of Kentucky College of Pharmacy, Lexington, Kentucky, USA
| | - Robert J DiDomenico
- Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Chicago, Illinois, USA
| | - Steven P Dunn
- Department of Pharmacy, University of Virginia Heart and Vascular Center, Charlottesville, Virginia, USA
| | - Jenna Cox
- Department of Pharmacy, Prisma Health Richland Hospital, Columbia, South Carolina, USA
| | - Long To
- Department of Pharmacy, Henry Ford Health System, Detroit, Michigan, USA
| | - Phillip Weeks
- Department of Pharmacy, Memorial Hermann Health System, Houston, Texas, USA
| | - Toby C Trujillo
- University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences/University of Colorado Hospital, Denver, Colorado, USA
| | - Douglas L Jennings
- Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, New York, USA.,Department of Pharmacy, New York-Presbyterian Hospital Columbia University Medical Center, New York, New York, USA
| |
Collapse
|
6
|
Carlier L, Devroe S, Budts W, Van Calsteren K, Rega F, Van de Velde M, Rex S. Cardiac interventions in pregnancy and peripartum – a narrative review of the literature. J Cardiothorac Vasc Anesth 2020; 34:3409-3419. [DOI: 10.1053/j.jvca.2019.12.021] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 11/19/2019] [Accepted: 12/12/2019] [Indexed: 12/17/2022]
|
7
|
Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy. J Am Coll Cardiol 2020; 75:207-221. [DOI: 10.1016/j.jacc.2019.11.014] [Citation(s) in RCA: 89] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 11/06/2019] [Accepted: 11/13/2019] [Indexed: 01/13/2023]
|
8
|
Abstract
PURPOSE OF REVIEW While the prognosis of peripartum cardiomyopathy (PPCM) is generally more favorable than other cardiomyopathies, PPCM can be associated with cardiogenic shock and significant maternal morbidity in young women. The management of a pregnant woman in cardiogenic shock necessitates consideration of harm to the fetus. This review focuses on the management of these women. RECENT FINDINGS A number of advances have increased the repertoire of therapies available to manage PPCM. Increased understanding of PPCM pathophysiology has led to a number of new and experimental medications. In the current era, mechanical circulatory support has been gaining a stronger presence in critical care and can be used in cardiogenic shock of the pregnant patient refractory to medical therapy. We discuss medical therapies, mechanical circulatory support, arrhythmia management, and a delivery plan in the setting of cardiogenic shock secondary to PPCM.
Collapse
|
9
|
Elkayam U, Schäfer A, Chieffo A, Lansky A, Hall S, Arany Z, Grines C. Use of Impella heart pump for management of women with peripartum cardiogenic shock. Clin Cardiol 2019; 42:974-981. [PMID: 31436333 PMCID: PMC6788473 DOI: 10.1002/clc.23249] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 08/09/2019] [Accepted: 08/14/2019] [Indexed: 12/26/2022] Open
Abstract
Background Percutaneous mechanical circulatory support (MCS), such as the Impella heart pump is a valuable option for cardiogenic shock (CS), although the use of Impella in CS due to peripartum cardiomyopathy (PPCM) is limited. Objective To assess outcomes in women with PPCM supported with an Impella device from the global catheter‐based ventricular assist device (cVAD) Registry. Methods and Results A total of 15 women with PPCM supported with Impella devices between November 2008 and October 2015 were included. Of the 15 women, five were treated at Hannover medical school and have been reported previously, the rest were managed at various US hospitals. The mean age was 30.0 ± 7.34 years, eight women were Caucasian, and seven were African‐American. The occurrence of PPCM was post‐delivery in eight (53.3%), at delivery in one (6.7%), and during gestation in four women (26.7%). At admission, all women had severe heart failure with a mean ejection fraction of 14.7 ± 6% and 13 women (86.7%) presented with CS. Prior to Impella, 100% were mechanically ventilated, 79% received inotropes/vasopressors, 20% supported with IABP, and 27% received veno‐arterial extracorporeal membrane oxygenation (VA ECMO) during Impella support. Two women (13.3%) died, and 13 (87.7%) survived to discharge. Eight women (53.3%) had a recovery of native heart function and six (40%) were bridged to durable left ventricular assist device (LVAD). Conclusion MCS with Impella devices can be successfully used as a bridge to early improvement, heart recovery, or successful implantation of durable LVAD in women with PPCM complicated by severe LV dysfunction.
Collapse
Affiliation(s)
- Uri Elkayam
- University of Southern California, Los Angeles, California
| | | | | | | | | | - Zoltan Arany
- University of Pennsylvania, Philadelphia, Pennsylvania
| | | |
Collapse
|
10
|
Glazier JJ, Kaki A. The Impella Device: Historical Background, Clinical Applications and Future Directions. Int J Angiol 2018; 28:118-123. [PMID: 31384109 DOI: 10.1055/s-0038-1676369] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The Impella device is a catheter-based miniaturized ventricular assist device. Using a retrograde femoral artery access, it is placed in the left ventricle across the aortic valve. The device pumps blood from left ventricle into ascending aorta and helps to maintain a systemic circulation at an upper rate between 2.5 and 5.0 L/min. This results in almost immediate and sustained unloading of the left ventricle, while increasing overall systemic cardiac output. The most common indications for using the Impella device are in the treatment of acute myocardial infarction complicated by cardiogenic shock and to facilitate high risk coronary angioplasty. Other indications include the treatment of cardiomyopathy with acute decompensation, postcardiotomy shock, and off-pump coronary bypass surgery. A growing body of observational and registry data suggest a potentially valuable role for the Impella system in reducing the mortality associated with cardiogenic shock. However, there are, as of yet, no randomized controlled trial data supporting this observation.
Collapse
Affiliation(s)
- James J Glazier
- Department of Cardiology, Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan
| | - Amir Kaki
- Department of Cardiology, Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan
| |
Collapse
|
11
|
Simon R, Yang S, Hameed AB. Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases. AJP Rep 2018; 8:e335-e342. [PMID: 30473907 PMCID: PMC6249133 DOI: 10.1055/s-0038-1675832] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Accepted: 09/12/2018] [Indexed: 01/14/2023] Open
Abstract
Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy. Data Sources Data were collected from PubMed/MedLine, ClinicalTrials.gov; the years 2007 to 2018 were searched for English-language articles. Search terms: "bromocriptine and peripartum cardiomyopathy", "bromocriptine and cardiomyopathy." Methods of Study Selection This search strategy yielded 171 articles. After excluding duplicates, 86 studies were reviewed. Sixty-one articles involving the treatment of PPCMP were included, and of these, 17 were case reports of patients with PPCMP treated with bromocriptine; these studies were included in this review. Tabulation, Integration, and Results Seventeen of these articles were case reports of patients with peripartum cardiomyopathy treated with bromocriptine that were included. Conclusion Bromocriptine seems to be a promising treatment, there is currently insufficient evidence for universal utilization of bromocriptine for all patients with PPCMP. Addition of bromocriptine to the standard heart failure therapy should be individualized.
Collapse
Affiliation(s)
- Rebecca Simon
- Irvine Department of Obstetrics and Gynecology, University of California, Orange, California
| | - Sophia Yang
- Irvine Department of Obstetrics and Gynecology, University of California, Orange, California
| | - Afshan B Hameed
- Irvine Department of Obstetrics and Gynecology, University of California, Orange, California
| |
Collapse
|
12
|
Sieweke JT, Pfeffer TJ, Berliner D, König T, Hallbaum M, Napp LC, Tongers J, Kühn C, Schmitto JD, Hilfiker-Kleiner D, Schäfer A, Bauersachs J. Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE 2018; 9:173-182. [PMID: 29792513 DOI: 10.1177/2048872618777876] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
INTRODUCTION Acute peripartum cardiomyopathy complicated by cardiogenic shock is a rare but life-threatening disease. A prolactin fragment is considered causal for the pathogenesis of peripartum cardiomyopathy. This analysis sought to investigate the role of early percutaneous mechanical circulatory support with micro-axial flow-pumps and/or veno-arterial extracorporeal membrane oxygenation in combination with the prolactin inhibitor bromocriptine in refractory cardiogenic shock complicating peripartum cardiomyopathy. METHODS AND RESULTS In this single-centre analysis, five peripartum cardiomyopathy patients with refractory cardiogenic shock received mechanical circulatory support with either Impella CP microaxial pump only (n=2) or in combination with veno-arterial extracorporeal membrane oxygenation (n=3) in the setting of biventricular failure. All patients were mechanically ventilated. In all cases mechanical circulatory support was combined with bromocriptine therapy and early administration of levosimendan. All patients survived the acute phase of refractory cardiogenic shock. Mechanical circulatory support using a micro-axial pump allowed to significantly reduce catecholamine dosage. Remarkably, early left ventricular support with micro-axial flow-pumps resulted in myocardial recovery whereas delayed Impella (mechanical circulatory support) implantation was associated with poor left ventricular recovery. CONCLUSION Mechanical circulatory support in patients with refractory cardiogenic shock complicating peripartum cardiomyopathy was associated with a 30-day survival of 100% and a favourable outcome. Notably, early left ventricular unloading combined with bromocriptine therapy was associated with left ventricular recovery. Therefore, an immediate transfer to a tertiary hospital experienced in mechanical circulatory support in combination with bromocriptine treatment seems indispensable for successful treatment of peripartum cardiomyopathy complicated by cardiogenic shock.
Collapse
Affiliation(s)
| | | | - Dominik Berliner
- Department of Cardiology and Angiology, Hannover Medical School, Germany
| | - Tobias König
- Department of Cardiology and Angiology, Hannover Medical School, Germany
| | | | - L Christian Napp
- Department of Cardiology and Angiology, Hannover Medical School, Germany
| | - Jörn Tongers
- Department of Cardiology and Angiology, Hannover Medical School, Germany
| | - Christian Kühn
- Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Germany
| | - Jan D Schmitto
- Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Germany
| | | | - Andreas Schäfer
- Department of Cardiology and Angiology, Hannover Medical School, Germany
| | - Johann Bauersachs
- Department of Cardiology and Angiology, Hannover Medical School, Germany
| |
Collapse
|
13
|
Labbene I, Arrigo M, Tavares M, Hajjej Z, Brandão JL, Tolppanen H, Feliot E, Gayat E, Ferjani M, Mebazaa A. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med 2016; 36:39-42. [PMID: 27436451 DOI: 10.1016/j.accpm.2016.02.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 02/22/2016] [Accepted: 02/24/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND Catecholamines and/or levosimendan have been proposed for haemodynamic restoration during cardiogenic shock (CS). In CS induced by post-partum cardiomyopathy (PPCM), levosimendan might be particularly favourable. The aim of this study was to evaluate the haemodynamic and echocardiographic effects of levosimendan in patients with CS, in particular in patients with PPCM-induced CS. METHODS Twenty-eight patients with refractory CS were retrospectively included in the study. Among them, a cohort of 8 women with PPCM-induced CS was included. All patients were treated with levosimendan (loading dose followed by a continuous infusion for 24 h) and were invasively monitored, including a pulmonary artery catheter, for 48hours. Echocardiographic measurements were performed at baseline and during follow-up. RESULTS Significant improvements in haemodynamic parameters were observed 48 h after starting levosimendan. The cardiac index increased (+1.2±0.6L/min, P<0.001) and filling pressures decreased (pulmonary artery occlusion pressure, PAOP: -11.2±4.3mmHg, P<0.001; right-atrial pressure, RAP: -6.1±4.9mmHg, P<0.001). The left ventricular ejection fraction was significantly higher at 48 h compared to baseline (38% [34-46%] versus 27% [22-30%], P<0.001). Despite similar characteristics at baseline, in the subgroup of patients with PPCM, more profound decongestive effects at 48hours were observed: PAOP (13±2 versus 17±4mmHg, P=0.007) and RAP (12±4 versus 17±4mmHg, P=0.006) were significantly lower in the PPCM subgroup compared to the non-PPCM subgroup. CONCLUSIONS Haemodynamics and left-ventricular ejection fraction rapidly improved after treatment with levosimendan. In patients with PPCM-induced CS, a more profound reduction of congestion was observed.
Collapse
Affiliation(s)
- I Labbene
- University of Tunis El Manar, department of anaesthesiology and critical care medicine, military hospital of Tunis, Tunis, Tunisia.
| | - M Arrigo
- Inserm UMR-S 942, Paris, France.
| | - M Tavares
- Serviço de cuidados intensivos, departamento de anestesia cuidados intensivos e emergência, hospital de Santo António, centro hospitalar do Porto, Porto, Portugal.
| | - Z Hajjej
- University of Tunis El Manar, department of anaesthesiology and critical care medicine, military hospital of Tunis, Tunis, Tunisia.
| | - J L Brandão
- Serviço de cuidados intensivos, departamento de anestesia cuidados intensivos e emergência, hospital de Santo António, centro hospitalar do Porto, Porto, Portugal.
| | | | - E Feliot
- Inserm UMR-S 942, Paris, France.
| | - E Gayat
- Inserm UMR-S 942, Paris, France; Université Paris Diderot, PRES Sorbonne Paris Cité, department of anaesthesiology and critical care medicine, AP-HP, Saint-Louis Lariboisière university hospitals, 2, rue Ambroise-Paré, 75010 Paris, France.
| | - M Ferjani
- University of Tunis El Manar, department of anaesthesiology and critical care medicine, military hospital of Tunis, Tunis, Tunisia.
| | - A Mebazaa
- Inserm UMR-S 942, Paris, France; Université Paris Diderot, PRES Sorbonne Paris Cité, department of anaesthesiology and critical care medicine, AP-HP, Saint-Louis Lariboisière university hospitals, 2, rue Ambroise-Paré, 75010 Paris, France.
| |
Collapse
|
14
|
Padilla C, Hernandez Conte A, Ramzy D, Sanchez M, Zhao M, Park D, Lubin L. Impella™ Left Ventricular Assist Device for Acute Peripartum Cardiomyopathy After Cesarean Delivery. ACTA ACUST UNITED AC 2016; 7:24-6. [DOI: 10.1213/xaa.0000000000000325] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
15
|
Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJ, Crespo-Leiro MG, De Boer RA, van der Meer P, Maack C, Mouquet F, Petrie MC, Piepoli MF, Regitz-Zagrosek V, Schaufelberger M, Seferovic P, Tavazzi L, Ruschitzka F, Mebazaa A, Sliwa K. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016; 18:1096-105. [DOI: 10.1002/ejhf.586] [Citation(s) in RCA: 133] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 04/27/2016] [Accepted: 05/08/2016] [Indexed: 12/28/2022] Open
Affiliation(s)
- Johann Bauersachs
- Department of Cardiology and Angiology; Medical School Hannover; Hannover Germany
| | - Mattia Arrigo
- Department of Cardiology, AP-HP; Lariboisière University Hospital; Paris France
- Department of Cardiology; University Heart Center, University Hospital Zurich; Zurich Switzerland
| | | | - Christian Veltmann
- Department of Cardiology and Angiology; Medical School Hannover; Hannover Germany
| | - Andrew J.S. Coats
- Monash-Warwick Alliance; Monash University, Australia, and University of Warwick; UK
| | | | - Rudolf A. De Boer
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Peter van der Meer
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Christoph Maack
- Klinik für Innere Medizin III; Universitätsklinikum des Saarlandes; Homburg Germany
| | | | - Mark C. Petrie
- Department of Cardiology; Golden Jubilee National Hospital and Glasgow University; Glasgow UK
| | - Massimo F. Piepoli
- Department of Cardiology; Guglielmo da Saliceto Hospital; Piacenza Italy
| | - Vera Regitz-Zagrosek
- Institute of Gender in Medicine; Charité Universitaetsmedizin Berlin, and German Center for Cardiovascular Research; Berlin Germany
| | - Maria Schaufelberger
- Section of Acute and Cardiovascular Medicine, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy; University of Gothenburg, Sahlgrenska University Hospital/Östra; Gothenburg Sweden
| | | | - Luigi Tavazzi
- Maria Cecilia Hospital, Gruppo Villa Maria Care and Research; Ettore Sansavini Health Science Foundation Cotignola Italy
| | - Frank Ruschitzka
- Department of Cardiology; University Heart Center, University Hospital Zurich; Zurich Switzerland
| | - Alexandre Mebazaa
- Department of Anesthesiology and Critical Care Medicine, AP-HP; Saint Louis Lariboisière University Hospitals; Paris France
| | - Karen Sliwa
- Hatter Institute for Cardiovascular Research in Africa & IDM, Inter-Cape Heart Group, Medical Research Council South Africa, Department of Medicine; University of Cape Town; Cape Town South Africa
| |
Collapse
|
16
|
Mennuni MG, Zavalloni D, Presbitero P. Role, risk and benefit of interventional cardiology procedures during pregnancy. Interv Cardiol 2015. [DOI: 10.2217/ica.14.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
17
|
Loyaga-Rendon RY, Pamboukian SV, Tallaj JA, Acharya D, Cantor R, Starling RC, Naftel D, Kirklin J. Outcomes of Patients With Peripartum Cardiomyopathy Who Received Mechanical Circulatory Support. Circ Heart Fail 2014; 7:300-9. [DOI: 10.1161/circheartfailure.113.000721] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Renzo Y. Loyaga-Rendon
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| | - Salpy V. Pamboukian
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| | - Jose A. Tallaj
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| | - Deepak Acharya
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| | - Ryan Cantor
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| | - Randall C. Starling
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| | - David Naftel
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| | - James Kirklin
- From the Cardiovascular Diseases Division (R.Y.L.-R., S.V.P., J.A.T., D.A.), Cardiothoracic Surgery Division (R.C., J.K., DN), Department of Epidemiology, School of Public Health (R.C.), University of Alabama at Birmingham; and Section of Heart Failure, Cleveland Clinic Foundation, OH (R.C.S.)
| |
Collapse
|